BlackRock
ACRV icon

BlackRock’s Acrivon Therapeutics ACRV Stock Holding History

BlackRock’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
239,112
+30,173
+14% +$51.3K ﹤0.01% 4620
2026
Q1 		$290K Buy
208,939
+3,815
+2% +$6.66K ﹤0.01% 4660
2025
Q4 		$494K Sell
205,124
-125,833
-38% -$274K ﹤0.01% 4486
2025
Q3 		$599K Sell
330,957
-76,665
-19% -$108K ﹤0.01% 4416
2025
Q2 		$485K Sell
407,622
-531,085
-57% -$729K ﹤0.01% 4452
2025
Q1 		$1.91M Sell
938,707
-6,789
-0.7% -$36.6K ﹤0.01% 4013
2024
Q4 		$5.69M Buy
945,496
+158,514
+20% +$1.15M ﹤0.01% 3668
2024
Q3 		$5.51M Buy
786,982
+19,962
+3% +$157K ﹤0.01% 3660
2024
Q2 		$4.45M Buy
767,020
+23,119
+3% +$186K ﹤0.01% 3726
2024
Q1 		$5.32M Buy
743,901
+178,069
+31% +$827K ﹤0.01% 3645
2023
Q4 		$2.78M Buy
565,832
+37,072
+7% +$196K ﹤0.01% 3911
2023
Q3 		$5.05M Sell
528,760
-4,595
-0.9% -$53.1K ﹤0.01% 3659
2023
Q2 		$6.91M Buy
533,355
+59,128
+12% +$716K ﹤0.01% 3583
2023
Q1 		$6.02M Buy
+474,227
New +$7.96M ﹤0.01% 3556

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's ACRV Position: Q2 2026 in Review

BlackRock increased its Acrivon Therapeutics (ACRV) stake by 14% in Q2 2026, buying an estimated $51.3K and bringing the position to 239,112 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #4620.

BlackRock first reported a position in ACRV in Q1 2023 and has held it in 14 quarters since. The position peaked at $6.91M in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • BlackRock held 239,112 shares of Acrivon Therapeutics worth $426K as of Q2 2026.
  • BlackRock bought 30,173 Acrivon Therapeutics shares in Q2 2026, an estimated $51.3K.
  • Acrivon Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4620 holding.
  • BlackRock first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • BlackRock's Acrivon Therapeutics position peaked at $6.91M in Q2 2023.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.